Johnson M, et al. - In view of the effectiveness seen with doravirine, a novel, nonnucleoside reverse transcriptase inhibitor, in treatment-naive adults with HIV-1, researchers conducted this open-label, active-controlled, noninferiority trial investigating the effectiveness and safety of switching from a stable antiretroviral regimen to a single-tablet, fixed-dose regimen of DOR/3TC/TDF. Adults with HIV-1 virologically suppressed for ≥6 months on two nucleoside reverse transcriptase inhibitors plus a boosted protease inhibitor, boosted elvitegravir, or a non-nucleoside reverse transcriptase inhibitor were randomly allocated to either switch to once-daily, single-tablet doravirine 100 mg with lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF) or to continue their current therapy for 24 weeks. There were 670 adults that participated. The noninferiority of switching to DOR/3TC/TDF vs continuation of the previous regimen was observed, with high rates of virologic suppression and low rates of virologic rebound. DOR/3TC/TDF had a promising safety profile over 48 weeks of treatment. Switching to DOR/3TC/TDF vs a boosted-PI regimen was linked with a favorable lipid profile. For maintaining viral suppression in patients considering a change in therapy, switching to once-daily DOR/3TC/TDF was suggested as an effective and generally well-tolerated option.